[1]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363-367.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
　Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):363-367.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
点击复制

分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
38
期数:
2014年第6期
页码:
363-367
栏目:
出版日期:
2014-11-25

文章信息/Info

Title:
Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy
作者:
汤敏敏1;  刘建中2;  武志芳2;  陆克义2;  李思进2;  高永举1;  武新宇1;  徐俊玲1
1. 郑州大学人民医院(河南省人民医院)核医学科, 450003;
2. 山西医科大学第一医院核医学科, 030001
Author(s):
Tang Min-min1;  Liu Jian-zhong2;  Wu Zhi-fang2;  Lu Ke-yi2;  Li Si-jin2;  Gao Yon-yu1;  Wu Xin-yu1;  Xu Jun-ling1
Department of Nuclear Medicine, Zhengzhou University People’S Hospital, Henan Provincial People’s Hospital, Zhengzhou 450003, China
关键词:
甲状腺肿瘤; 碘放射性同位素; 体层摄影术; 发射型计算机; 单光子
Keywords:
Thyroid neoplasms; Iodine radioisotopes; Tomography; emission-computed; single-photon
DOI:
10.3760/cma.j.issn.1673-4114.2014.06.004
摘要:
目的 评估分化型甲状腺癌(DTC)患者131I治疗后体内残留放射性活度。方法 本研究共纳入了35例DTC患者,分为"清甲"(20例)与"清灶"(15例)组,分别于服131I后2、6、24、48、72 h进行131I全身显像及1m处当量剂量率的测定,以2h时显像计数和活度作为总计数和总活度。根据各时间点显像计数与2h的显像计数比值间接估算体内残留放射性活度,并估算患者体内残留放射性活度达到400 MBq时的1m处当量剂量率。统计学分析采用直线相关与回归分析。结果 "清甲"组服131I后2、6、24、48、72 h体内残留131I活度占服131I总活度的百分比分别为99%±4%、86%±6%、35%±10%、12%±8%、7%±8%, "清灶"组分别为99%±1%、91%±7%、47%±17%、11%±9%、4%±6%. "清甲"组服131I后2、6、24、48、72 h的1m处当量剂量率分别为(157±37)、(120±36)、(35±13)、(11±9)、(9±11)μSv/h,"清灶"组分别为(234±43)、(186±51)、(49±20)、(12±11)、(4±6)μSv/h.体内残留的放射性活度与1m处当量剂量率呈正相关(r=0.87,P<0.001)."清甲"与"清灶"组服131I后48、72 h体内残留放射性活度分别为(432±292)、(265±281) MBq及(731±701)、(277±470) MBq,对应的1m处当量剂量率为8~11μSv/h.结论 DTC患者服131I后48~72 h体内残留放射性活度达到国家标准规定的400 MBq时,即DTC患者1m处当量剂量率达到8~11μSv/h时方可出院。
Abstract:
Objective To estimate the residual activities of patients with differentiated thyroid cancer (DTC)after administration of 131I for post-operative therapy.Methods Thirty-five DTC patients were divided into thyroid remnant 131I ablation therapy group (20 cases)and 131I treatment for metastatic lesions group (15 cases).131I whole body scan and the determination of equivalent dose rate at 1 meter point were performed to estimate multi-temporal residual activities in each patient 2,6,24,48,and 72 h after administration of therapeutic doses of 131I,respectively.The percentage of residual activities was indirectly estimated in vivo through ratio of multi-temporal calculation of radioactive counts on 131I whole body imaging versus that at 2 h (radioactive counts on 131I whole body imaging and 131I activity at 2 h were regarded as total counts and activities),and furthermore the equivalent dose rate at 1 meter point was indirectly estimated when the residual activities reach to 400 MBq.Correlation and regression analysis were used to evaluate the relationship between residual activities and the equivalent dose rate at 1 m.Statistical significance was accepted at P<0.05.Results The percentage of residual activities were 99%±4%,86%±6%,35%±10%,12%±8%,7%±8% in thyroid remnant 131I ablation therapy group,and 99%±1%,91%±7%,47%±17%,11%±9% and 4%±6% in 131I treatment for metastatic lesions group at 2,6,24,48 and 72 h after administration of 131I,respectively.The equivalent dose rates at 1 m point were (157±37), (120±36), (35±13), (11±9)and (9±11)μSv/h in thyroid remnant 131I ablation therapy group and (234±43), (186±51), (49±20), (12±11)and (4±6)μSv/h in 131I treatment for metastatic lesions group at 2,6,24,48 and 72 h after administration of 131I,respectively.There is a positive correlation between residual activities and equivalent dose rate at 1 m (r=0.87,P<0.001).The residual activities were (432±292), (265±281)MBq 48 and 72 h after administration of 131I in thyroid remnant 131I ablation therapy group and (731±701), (277±470)MBq in 131I treatment for metastatic lesions group.At the same point of time,the corresponding range of equivalent dose rate at 1 m was from 8 to 11 μSv/h.Conclusion The in vivo residual activity reaches the national standard of 400 MBq in patients with differentiated thyroid cancer 48~72 h after serving 131I and the range of equivalent dose rate at 1 m was from 8 to 11 μSv/h.At this time,radiation isolation could be discharged.

参考文献/References:

[1] American Thyroid Association(ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper DS,Doherty GM,et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19(11):1167-1214..
[2] 张桂芝,谭建,刘雪辉,等.131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J].中华核医学杂志,2010,30(4):259-263.
[3] 张洁,石洪成.分化型甲状腺癌131I治疗的现状[J].国际放射医学核医学杂志,2009,33(3):163-167.
[4] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志,2013,33(2):96-115.
[5] 匡安仁.131I治疗分化型甲状腺癌[M].1版.北京:人民卫生出版社,2013:102-103.
[6] 刘斌,王建涛,牟达,等.131I治疗分化型甲状腺癌血液和骨髓的吸收剂量及剂量学导向治疗法[J].中华核医学杂志,2010,30(2):142-144.
[7] Lassmann M,H?:nscheid H,Chiesa C,et al.EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I:blood and bone marrow dosimetry in differentiated thyroid cancer therapy[J].Eur J Nucl Med Mol Imaging,2008,35(7):1405-1412.
[8] Sieqel JA.Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials:outpatient iodine-131 anti-B1 therapy[J].J Nucl Med,1998,39(8 Suppl):S28-33.
[9] 中华人民共和国卫生部.GBZ120-2006临床核医学放射卫生防护标准[S].北京:人民卫生出版社,2006.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[13]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[14]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[15]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
　Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[16]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
　Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[17]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
　Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[18]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
　HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[19]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
　YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
[20]董峰,周荫保.分化型甲状腺癌术后131I清甲效果的影响因素[J].国际放射医学核医学杂志,2010,34(1):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]
　DONG Feng,ZHOU Yin-bao.Influencing factors of radioiodine ablation of posts-urgical thyroid remnants in differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]

备注/Memo

备注/Memo:
收稿日期:2014-06-05。
通讯作者:刘建中(Email:liujz.3@163.com)
更新日期/Last Update: 1900-01-01